Metabolic Research Peptides

Incretin-based research peptides for studies on metabolic regulation, adiposity and glycaemic control. Retatrutide (LY3437943) as the first GLP-1/GIP/glucagon triple agonist with up to 24 percent weight loss in Phase 2 (NEJM 2023) and positive Phase 3 readouts from TRIUMPH-4. Alongside it, AOD-9604 as hGH fragment 177-191 for targeted lipolysis research without systemic incretin activity. Both compounds ship with Janoshik third-party COAs, EU warehouse, DHL premium shipping with a reduced 8-euro rate inside Germany.

Featured in this category

AOD-9604

Modified hGH fragment (177-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.

from €36.99View product →

Retatrutide

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

from €99.99View product →

Tirzepatide

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

from €79.99View product →

All products

-16%

Metabolic

AOD-9604

Modified hGH fragment (177-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.

€36.99

€43.99

-16%

Metabolic

Retatrutide

€99.99

€118.99

Metabolic

Tirzepatide

€79.99

Back soon

Metabolic

Cagrilintide

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

€79.99

€94.99

Notify me

Related research

August 14, 2026

Eli Lilly's Six Retatrutide Lawsuits: What They Actually Claim, and What They Mean for Europe (August 2026)

Lilly sued six US retatrutide sellers on 12 August 2026 and called on payment companies to act. What the cases claim, what they do not, and the EU view.

August 14, 2026

Tirzepatide and Cardiovascular Events: Inside the 52,971-Patient BMJ Cohort Study (August 2026)

A BMJ cohort study of 52,971 adults with type 2 diabetes linked tirzepatide to a 32% lower one-year hazard of major cardiovascular events. The details.

July 31, 2026

262 trials, 19 drugs: where retatrutide actually stands in the BMJ analysis

The BMJ network meta-analysis compares 19 drugs across 262 trials. For retatrutide, it gives no figure of its own, only a range shared across three drugs.